4-(3-(3-methylpyridin-4-yl)phenyl)-4-(2-(trifluoromethyl)phenylsulfonamido)butanoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(3-(3-methylpyridin-4-yl)phenyl)-4-(2-(trifluoromethyl)phenylsulfonamido)butanoic acid
• 英文别名: 4-[3-(3-Methylpyridin-4-yl)phenyl]-4-[[2-(trifluoromethyl)phenyl]sulfonylamino]butanoic acid；4-[3-(3-methylpyridin-4-yl)phenyl]-4-[[2-(trifluoromethyl)phenyl]sulfonylamino]butanoic acid
• 化学式: C₂₃H₂₁F₃N₂O₄S
• 分子量: 478.492
• InChiKey: MORYKUNDJNWLEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-三氟甲基苯磺酰氯 在 盐酸 、 四羟基二硼 、 XPhos Pd G2 、 水 、 potassium acetate 、 三乙胺 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 7.17h， 生成 4-(3-(3-methylpyridin-4-yl)phenyl)-4-(2-(trifluoromethyl)phenylsulfonamido)butanoic acid
  参考文献：
  名称：

  [EN] NOVEL NON-SYSTEMIC TGR5 AGONISTS
  [FR] NOUVEAUX AGONISTES DE TGR5 NON SYSTÉMIQUES

  摘要：

  公开号：

  WO2018005801A3

文献信息

• Non-systemic TGR5 agonists
  申请人：Venenum Biodesign, LLC

  公开号：US11236055B2

  公开（公告）日：2022-02-01

  The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.

  本发明涉及式（I）和式（II）的磺酰胺化合物或其药学上可接受的盐。本发明的磺酰胺化合物是有用的非全身性 TGR5 激动剂，可用于治疗人类糖尿病疾病。本发明提供了一种含有式（I）和式（II）磺酰胺化合物的药物组合物及其制造方法，以及一种通过给药治疗代谢紊乱患者的方法。本发明的化合物可与其他抗糖尿病药物联合使用。
• NOVEL NON-SYSTEMIC TGR5 AGONISTS
  申请人：Venenum Biodesign, LLC

  公开号：US20200308122A1

  公开（公告）日：2020-10-01

  The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.
• [EN] NOVEL NON-SYSTEMIC TGR5 AGONISTS<br/>[FR] NOUVEAUX AGONISTES DE TGR5 NON SYSTÉMIQUES
  申请人：VENENUM BIODESIGN LLC

  公开号：WO2018005801A3

  公开（公告）日：2018-02-01